US regulators approve Moderna flu vaccine
Vaccine manufacturer Moderna said Wednesday the U.S. Food and Drug Administration (FDA) had approved its new influenza vaccine, nearly six months after the regulator briefly rejected an application for review.
The U.S. Food and Drug Administration (FDA) has approved Moderna's first mRNA-based influenza vaccine, mFLUSIVA, for use in all adults aged 50 and older. The vaccine manufacturer announced this news on Wednesday, nearly six months after the regulator briefly rejected the application for review. Moderna expects to make the vaccine available for eligible populations in the U.S. for the 2026-2027 respiratory virus season.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — read the original for the full account.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
